BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18324400)

  • 21. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma.
    Kircheis R; Küpcü Z; Wallner G; Wagner E
    Cytokines Cell Mol Ther; 1998 Jun; 4(2):95-103. PubMed ID: 9681248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survivin minigene DNA vaccination is effective against neuroblastoma.
    Fest S; Huebener N; Bleeke M; Durmus T; Stermann A; Woehler A; Baykan B; Zenclussen AC; Michalsky E; Jaeger IS; Preissner R; Hohn O; Weixler S; Gaedicke G; Lode HN
    Int J Cancer; 2009 Jul; 125(1):104-14. PubMed ID: 19291796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine.
    Comes A; Rosso O; Orengo AM; Di Carlo E; Sorrentino C; Meazza R; Piazza T; Valzasina B; Nanni P; Colombo MP; Ferrini S
    J Immunol; 2006 Feb; 176(3):1750-8. PubMed ID: 16424205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
    Kowalczyk A; Wierzbicki A; Gil M; Bambach B; Kaneko Y; Rokita H; Repasky E; Fenstermaker R; Brecher M; Ciesielski M; Kozbor D
    Cancer Immunol Immunother; 2007 Sep; 56(9):1443-58. PubMed ID: 17597331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model.
    Chakrabarti L; Morgan C; Sandler AD
    PLoS One; 2015; 10(6):e0129237. PubMed ID: 26079374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
    Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
    Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
    Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
    Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity.
    Rigo V; Corrias MV; Orengo AM; Brizzolara A; Emionite L; Fenoglio D; Filaci G; Croce M; Ferrini S
    Cancer Immunol Immunother; 2014 May; 63(5):501-11. PubMed ID: 24647609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model.
    Williams EL; Dunn SN; James S; Johnson PW; Cragg MS; Glennie MJ; Gray JC
    Clin Cancer Res; 2013 Jul; 19(13):3545-55. PubMed ID: 23649004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.
    Balza E; Carnemolla B; Mortara L; Castellani P; Soncini D; Accolla RS; Borsi L
    Int J Cancer; 2010 Jul; 127(1):101-10. PubMed ID: 19877124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications.
    Morandi F; Chiesa S; Bocca P; Millo E; Salis A; Solari M; Pistoia V; Prigione I
    Neoplasia; 2006 Oct; 8(10):833-42. PubMed ID: 17032500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells.
    Salcedo R; Stauffer JK; Lincoln E; Back TC; Hixon JA; Hahn C; Shafer-Weaver K; Malyguine A; Kastelein R; Wigginton JM
    J Immunol; 2004 Dec; 173(12):7170-82. PubMed ID: 15585838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer.
    NoeDominguez-Romero A; Zamora-Alvarado R; Servín-Blanco R; Pérez-Hernández EG; Castrillon-Rivera LE; Munguia ME; Acero G; Govezensky T; Gevorkian G; Manoutcharian K
    Hum Vaccin Immunother; 2014; 10(11):3201-13. PubMed ID: 25483665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
    Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
    Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory.
    Jing W; Gershan JA; Johnson BD
    Blood; 2009 Apr; 113(18):4449-57. PubMed ID: 19182203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.
    Zimmerman M; Yang D; Hu X; Liu F; Singh N; Browning D; Ganapathy V; Chandler P; Choubey D; Abrams SI; Liu K
    PLoS One; 2010 Nov; 5(11):e14076. PubMed ID: 21124930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
    Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
    Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma.
    Rigo V; Emionite L; Daga A; Astigiano S; Corrias MV; Quintarelli C; Locatelli F; Ferrini S; Croce M
    Sci Rep; 2017 Oct; 7(1):14049. PubMed ID: 29070883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adoptive transfer of cytotoxic T lymphocytes induced by CD86-transfected tumor cells suppresses multi-organ metastases of C1300 neuroblastoma in mice.
    Enomoto A; Kato K; Yagita H; Okumura K
    Cancer Immunol Immunother; 1997 Jun; 44(4):204-10. PubMed ID: 9222278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.